Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials

Lancet

Volumn 355, Issue 9214, 2000, Pages 1491-1498

  Dalesio, O ^a   Van Tinteren, H ^a   Clarke, M ^a   Peto, R ^a   Schroder, F H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; FLUTAMIDE; NILUTAMIDE;

AGED; ANDROGEN RELEASE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; FOLLOW UP; HUMAN; MALE; META ANALYSIS; METASTASIS; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

EID: 0034728828     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02163-2     Document Type: Article

References (44)

1. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet. 346:1995;265-269.
2. Van Tinteren H., Dalesio O. Systematic overview (meta-analysis) of all randomised trials of treatment of prostate cancer. Cancer. 72:1993;3847-3850.
3. Early Breast Cancer Trialists' Collaborative Group. Systematic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
4. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med. 333:1995;1444-1455.
5. Morote J., Vallejo C., Lorente J.A.et al. [Final results of complete hormone blockade versus monotherapy in prostatic metastatic cancer. PSA implications]. [Spanish]. Acta Urol Esp. 19:1995;604-610.
6. Kuhn J.M., Billebaud T., Navratil H.et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med. 321:1989;413-418.
7. Le Duc A., Delchambre J., Cariou G. Comparison of Anandron and a placebo given beginning the day after surgical castration to patients with bone pain due to metastases of prostate cancers. Eur Urol (IXth Congress). 18(Suppl 1):1990;S385.
8. Sander S., Nissen-Meyer R., Aakvaag A. Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. a randomized clinical and endocrine study Scand J Urol Nephrol. 16:1982;193-197.
9. Yamanaka H., Imai K., Mashimo T.et al. Fundamental study on the implantable LH-RH agonist/polymer and its use in a randomized trial for prostate cancer. Prog Clin Biol Res. 357:1990;135-143.
10. Brisset J.M., Boccon-Gibod L., Botto H.et al. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo. Prog Clin Biol Res. 243A:1987;411-422.
11. Navratil H. Double-blind study of anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Prog Clin Biol Res. 243A:1987;401-410.
12. Béland G., Elhilali M., Fradet Y.et al. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer. 66(5 suppl):1990;1074-1079.
13. Namer M., Toubol J., Caty A.et al. A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer. J Steroid Biochem Mol Biol. 37:1990;909-915.
14. Bertagna C., De Géry A., Hucher M., Francois J.P., Zanirato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer: a meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol. 73:1994;396-402.
15. Dijkman G.A., Janknegt R.A., De Reyke T.M., Debruyne F.M.J. Long-term efficacy and safety of Nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol. 158:1997;160-163.
16. Knönagel H., Bolle J.F., Hering F.et al. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study]. [German]. Helv Chir Acta. 56:1989;343-345.
17. Crawford E.D., Kasimis B.S., Gandara D.et al. A randomized, controlled clinical trial of Leuprolide and Anandron versus Leuprolide and placebo for advanced prostate cancer. Proc Am Soc Clin Oncol. 9:1990;A523.
18. Crawford E.D., Eisenberger M.A., McLeod D.G.et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321:1989;419-424.
19. Schulze H., Kaldenhoff H., Senge T. Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer. Urol Int. 43:1988;193-197.
20. Tyrrell C.J., Altwein J.E., Klippel F.et al. Multicenter randomized trial comparing zoladex with zoladex plus flutamide in the treatment of advanced prostate cancer. Cancer. 72:1993;3878-3879.
21. Denis L.J., Keuppens F., Smith P.H.et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol. 33:1998;144-151.
22. Iversen P., Rasmussen F., Klarskov P., Christensen I.J. Long-term results of Danish Prostatic Cancer Group trial 86; goserelin acetate plus flutamide versus orchidectomy in advanced prostate cancer. Cancer. 72(suppl 12):1993;3851-3854.
23. Fourcade R.O., Colombel P., Mangin M. Zoladex plus flutamide versus Zoladex plus placebo in advanced prostatic carcinoma: extended follow-up of the French multicentre study. Murphy G., Khoury S., Chatelain C., Denis L. Proceedings of the 3rd International Symposium on Recent Advances in Urological Cancer: Diagnosis and Treatment, June 1992. 1993;102-106.
24. Zalcberg J.R., Raghavan D., Marshall V., Thompson P.J. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate. an Australian multicentre trial Br J Urol. 77:1996;865-869.
25. Delaere K.P., Boccon-Gibod L., Corrado F.et al. Randomized, double-blind, parrallel group study of flutamide and orchiectomy versus placebo and orchiectomy in men with D2 adenocarcinoma of the prostate. Proc ECCO-. 4:1987;68.
26. Boccardo F., Pace M., Rubagotti A.et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. the Italian Prostatic Cancer Project (PONCAP) Study Group Eur J Cancer. 29A:1993;1088-1093.
27. Ferrari P., Castagnetti G., Ferrari G., Baisi B., Dotti A. Combination treatment versus LHRH alone in advanced prostatic cancer. Urol Int. 56(suppl 1):1996;13-17.
28. Eisenberger M.A., Blumenstein B.A., Crawford E.D.et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer (NCI INT-0105 SWOG/ECOG). N Engl J Med. 339:1998;1036-1042.
29. Bono A.V., DiSilverio F., Robustelli della Cuna G.et al. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Urol Int. 60(suppl 1):1998;18-24.
30. Robinson M.R., Smith P.H., Richards B., Newling D.W., de Pauw M., Sylvester R. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol. 28:1995;273-283.
31. Di Silverio F., Serio M., D'Eramo G., Sciarra F. Zoladex vs zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter italian study. Eur Urol. 18:1990;54-61.
32. De Voogt H.J., Studer U., Schroder F.H.et al. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. final analysis of EORTC GU Group Trial 30843 Eur Urol. 33:1998;152-158.
33. Jorgensen T., Tveter K.J., Jorgensen L.H. Total androgen suppression. experience from the Scandinavian Prostatic Cancer Group Study No 2. Eur Urol. 24:1993;466-470.
34. Thorpe S.C., Azmatullah S., Fellows G.J., Gingell J.C., O'Boyle P.J. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol. 29:1996;47-54.
35. Theib M., Wirth M., Tunn U.et al. Triptorelin-Cyproteronacetat versus Triptorelin-Placebo. Multizentrische Phase III-Studie an 222 Patienten mit fortgeschrittenem Prostata-Karzinom Urologe A. 1996;S41.
36. Rana A., Habib F.K., Halliday P.et al. A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur J Cancer. 31:1995;871-875.
37. Klosterhalfen H., Becker H. 10-Jahres-Ergebnisse einer randomisierten Prospectivstudie beim metastasierten Prostatakarzinom. Akt Urol. 18:1987;234-236.
38. Klosterhalfen H., Burchardt P., Wartke U.S. Derzeitiger stand einer prospektiven prostata-carninom-studie. Urologe A. 12:1973;304-307.
39. Williams G., Asopa R., Abel P.D., Smith C. Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer. Br J Urol. 65:1990;504-508.
40. Waxman J., Pandha H. Antiandrogens in treatment of prostate cancer. Lancet. 346:1995;1030.
41. Labrie F., Crawford D. Antiandrogens in the treatment of prostate cancer. Lancet. 346:1995;1030-1031.
42. Quartey P. Antiandrogens in the treatment of prostate cancer. Lancet. 346:1995;1031.
43. Blumenstein B.A. Overview analysis issues, using combined androgen deprivation overview analysis as an example. Urol Oncol. 1:1995;95-100.
44. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.